Financhill
Sell
26

MOLN Quote, Financials, Valuation and Earnings

Last price:
$3.57
Seasonality move :
-17.8%
Day range:
$3.59 - $3.59
52-week range:
$3.36 - $12.22
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
18.50x
P/B ratio:
0.91x
Volume:
497
Avg. volume:
2.1K
1-year change:
-46.42%
Market cap:
$132.4M
Revenue:
$5.6M
EPS (TTM):
-$1.92

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
MOLN
Molecular Partners AG
-- -$0.53 -100% -3.62% $10.76
ACIU
AC Immune SA
$381.2K -$0.23 215.05% -22.94% $9.18
ADXN
Addex Therapeutics
$242.8K -- 2.35% -- $30.00
CRSP
CRISPR Therapeutics AG
$13M -$1.30 -96.36% -7.71% $81.75
NLSP
NLS Pharmaceutics
-- -- -- -- --
ONC
BeOne Medicines
$1.3B $0.27 29.74% -70.04% $330.95
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
MOLN
Molecular Partners AG
$3.59 $10.76 $132.4M -- $0.00 0% 18.50x
ACIU
AC Immune SA
$2.04 $9.18 $205.2M -- $0.00 0% 6.27x
ADXN
Addex Therapeutics
$8.83 $30.00 $9.4M 1.72x $0.00 0% 24.16x
CRSP
CRISPR Therapeutics AG
$56.80 $81.75 $4.9B -- $0.00 0% --
NLSP
NLS Pharmaceutics
$2.10 -- $9.5M -- $0.00 0% --
ONC
BeOne Medicines
$250.30 $330.95 $27.1B -- $0.00 0% 6.43x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
MOLN
Molecular Partners AG
-- 1.488 -- 14.08x
ACIU
AC Immune SA
-- 3.489 -- 1.50x
ADXN
Addex Therapeutics
-- 1.447 -- 4.36x
CRSP
CRISPR Therapeutics AG
-- 2.371 -- 21.97x
NLSP
NLS Pharmaceutics
-- 4.954 -- --
ONC
BeOne Medicines
20.88% 0.624 3.14% 1.64x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
MOLN
Molecular Partners AG
-- -$17.9M -37.36% -37.36% -2407.93% -$19.5M
ACIU
AC Immune SA
-- -$21.5M -42.34% -42.34% -1916.67% -$21.3M
ADXN
Addex Therapeutics
-- -$674K 91.08% 91.08% -2836.3% -$665.6K
CRSP
CRISPR Therapeutics AG
-$57.5M -$148.4M -18.65% -18.65% -184.54% -$54.2M
NLSP
NLS Pharmaceutics
-- -- -- -- -- --
ONC
BeOne Medicines
$952.3M $11.1M -8.9% -11.54% 0.99% -$72.3M

Molecular Partners AG vs. Competitors

  • Which has Higher Returns MOLN or ACIU?

    AC Immune SA has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -1922.12%. Molecular Partners AG's return on equity of -37.36% beat AC Immune SA's return on equity of -42.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.50 $165M
    ACIU
    AC Immune SA
    -- -$0.21 $107.6M
  • What do Analysts Say About MOLN or ACIU?

    Molecular Partners AG has a consensus price target of $10.76, signalling upside risk potential of 199.84%. On the other hand AC Immune SA has an analysts' consensus of $9.18 which suggests that it could grow by 349.89%. Given that AC Immune SA has higher upside potential than Molecular Partners AG, analysts believe AC Immune SA is more attractive than Molecular Partners AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    ACIU
    AC Immune SA
    3 0 0
  • Is MOLN or ACIU More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison AC Immune SA has a beta of 1.618, suggesting its more volatile than the S&P 500 by 61.81%.

  • Which is a Better Dividend Stock MOLN or ACIU?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AC Immune SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. AC Immune SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or ACIU?

    Molecular Partners AG quarterly revenues are $787.5K, which are smaller than AC Immune SA quarterly revenues of $1.1M. Molecular Partners AG's net income of -$18.6M is higher than AC Immune SA's net income of -$21.2M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while AC Immune SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.50x versus 6.27x for AC Immune SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    18.50x -- $787.5K -$18.6M
    ACIU
    AC Immune SA
    6.27x -- $1.1M -$21.2M
  • Which has Higher Returns MOLN or ADXN?

    Addex Therapeutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -2841.85%. Molecular Partners AG's return on equity of -37.36% beat Addex Therapeutics's return on equity of 91.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.50 $165M
    ADXN
    Addex Therapeutics
    -- -$1.33 $13.1M
  • What do Analysts Say About MOLN or ADXN?

    Molecular Partners AG has a consensus price target of $10.76, signalling upside risk potential of 199.84%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 239.75%. Given that Addex Therapeutics has higher upside potential than Molecular Partners AG, analysts believe Addex Therapeutics is more attractive than Molecular Partners AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    ADXN
    Addex Therapeutics
    0 0 0
  • Is MOLN or ADXN More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.646, suggesting its more volatile than the S&P 500 by 64.6%.

  • Which is a Better Dividend Stock MOLN or ADXN?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or ADXN?

    Molecular Partners AG quarterly revenues are $787.5K, which are larger than Addex Therapeutics quarterly revenues of $62.3K. Molecular Partners AG's net income of -$18.6M is lower than Addex Therapeutics's net income of -$1.6M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is 1.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.50x versus 24.16x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    18.50x -- $787.5K -$18.6M
    ADXN
    Addex Therapeutics
    24.16x 1.72x $62.3K -$1.6M
  • Which has Higher Returns MOLN or CRSP?

    CRISPR Therapeutics AG has a net margin of -2408.81% compared to Molecular Partners AG's net margin of -106.6%. Molecular Partners AG's return on equity of -37.36% beat CRISPR Therapeutics AG's return on equity of -18.65%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.50 $165M
    CRSP
    CRISPR Therapeutics AG
    -- -$1.58 $1.9B
  • What do Analysts Say About MOLN or CRSP?

    Molecular Partners AG has a consensus price target of $10.76, signalling upside risk potential of 199.84%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.75 which suggests that it could grow by 43.93%. Given that Molecular Partners AG has higher upside potential than CRISPR Therapeutics AG, analysts believe Molecular Partners AG is more attractive than CRISPR Therapeutics AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    CRSP
    CRISPR Therapeutics AG
    11 10 1
  • Is MOLN or CRSP More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

  • Which is a Better Dividend Stock MOLN or CRSP?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or CRSP?

    Molecular Partners AG quarterly revenues are $787.5K, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. Molecular Partners AG's net income of -$18.6M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.50x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    18.50x -- $787.5K -$18.6M
    CRSP
    CRISPR Therapeutics AG
    -- -- $35M -$136M
  • Which has Higher Returns MOLN or NLSP?

    NLS Pharmaceutics has a net margin of -2408.81% compared to Molecular Partners AG's net margin of --. Molecular Partners AG's return on equity of -37.36% beat NLS Pharmaceutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.50 $165M
    NLSP
    NLS Pharmaceutics
    -- -- --
  • What do Analysts Say About MOLN or NLSP?

    Molecular Partners AG has a consensus price target of $10.76, signalling upside risk potential of 199.84%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 11328.57%. Given that NLS Pharmaceutics has higher upside potential than Molecular Partners AG, analysts believe NLS Pharmaceutics is more attractive than Molecular Partners AG.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    NLSP
    NLS Pharmaceutics
    0 0 0
  • Is MOLN or NLSP More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock MOLN or NLSP?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or NLSP?

    Molecular Partners AG quarterly revenues are $787.5K, which are larger than NLS Pharmaceutics quarterly revenues of --. Molecular Partners AG's net income of -$18.6M is higher than NLS Pharmaceutics's net income of --. Notably, Molecular Partners AG's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.50x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    18.50x -- $787.5K -$18.6M
    NLSP
    NLS Pharmaceutics
    -- -- -- --
  • Which has Higher Returns MOLN or ONC?

    BeOne Medicines has a net margin of -2408.81% compared to Molecular Partners AG's net margin of 0.11%. Molecular Partners AG's return on equity of -37.36% beat BeOne Medicines's return on equity of -11.54%.

    Company Gross Margin Earnings Per Share Invested Capital
    MOLN
    Molecular Partners AG
    -- -$0.50 $165M
    ONC
    BeOne Medicines
    85.23% -- $4.4B
  • What do Analysts Say About MOLN or ONC?

    Molecular Partners AG has a consensus price target of $10.76, signalling upside risk potential of 199.84%. On the other hand BeOne Medicines has an analysts' consensus of $330.95 which suggests that it could grow by 32.22%. Given that Molecular Partners AG has higher upside potential than BeOne Medicines, analysts believe Molecular Partners AG is more attractive than BeOne Medicines.

    Company Buy Ratings Hold Ratings Sell Ratings
    MOLN
    Molecular Partners AG
    3 1 0
    ONC
    BeOne Medicines
    15 1 0
  • Is MOLN or ONC More Risky?

    Molecular Partners AG has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

  • Which is a Better Dividend Stock MOLN or ONC?

    Molecular Partners AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Molecular Partners AG pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios MOLN or ONC?

    Molecular Partners AG quarterly revenues are $787.5K, which are smaller than BeOne Medicines quarterly revenues of $1.1B. Molecular Partners AG's net income of -$18.6M is lower than BeOne Medicines's net income of $1.3M. Notably, Molecular Partners AG's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Molecular Partners AG is 18.50x versus 6.43x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    MOLN
    Molecular Partners AG
    18.50x -- $787.5K -$18.6M
    ONC
    BeOne Medicines
    6.43x -- $1.1B $1.3M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Roku Stock Undervalued Now?
Is Roku Stock Undervalued Now?

At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…

Will Microsoft Be a $5 Trillion Stock?
Will Microsoft Be a $5 Trillion Stock?

Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…

Where Will C3.ai Stock Be in 1 Year?
Where Will C3.ai Stock Be in 1 Year?

C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…

Stock Ideas

Buy
69
Is NVDA Stock a Buy?

Market Cap: $4T
P/E Ratio: 56x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 43x

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
58
INKT alert for Jul 12

MiNK Therapeutics [INKT] is up 727.94% over the past day.

Buy
51
NEGG alert for Jul 12

Newegg Commerce [NEGG] is up 74.03% over the past day.

Buy
68
ATRO alert for Jul 12

Astronics [ATRO] is up 16.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock